Questions discussed in this category
For patients not on study, would you consider replacing missed doses of peg with a non-asparaginase based chemotherapy?
There are conflicting reports whether it contributes to renal insufficiency. If you do switch, what is your preferred TKI in this scenario?
If so, how long do you continue medication and when do you discontinue?
Does treatment with surgical resection versus radiation alone change your man...
If so, how often do you check these labs?
Patient initially achieved CR with VAC-IE with resolution of presumed lung mets and 100% necrosis in LLE primary tumor on BKA. Then was NED again afte...
How is your approach different from or similar to those who undergo surgical menopause?
What are indications to order gene mutation studies (e.g. ELANE) and how would it help the patient?
What would you recommend within the first year after ATG and thereafter if still maintained on cyclosporine?
What would be your next treatment for a young adult patient with medulloblastoma refractory to repeat resection, craniospinal irradiation, and initial...
Would surgical margins, evidence of angiolymphatic spread, number of lymph nodes removed during surgery inform your decision?
If not, how do you choose GVHD prophylaxis regimen? Is there a preference?
E.g. would you dose-reduce or continue at same dose?
Baseline ANC was in the normal range
How reliable is somatic testing to detect an underlying germline predisposition?
Is skin testing advised prior to trialing alternative?
iPET2 and iPET4 showed Deauville 5 response. CT biopsy after 4 cycles was negative. Patient is currently scheduled for 2 additional cycles of ABVD.
Ewing sarcoma of the right lung, status post bi-lobectomy and adjuvant VDC/IE, with recurrence 6 years in the right lung only. He has reached a cumula...
If so, what platelet count threshold would you use? Would age impact your decision? Would you do a bone marrow to rule out primary MPD in adults if th...
Do you ever add prophylactic Keppra (levetiracetam) for glioblastoma patients without a seizure history based on data such as this study (nature.com) ...
I've seen a handful of fatal radiation pneumonitis associated with rapid steroid tapers by the non-treating physicians. How do you recommend prescribi...
How does graft function play into your decision making? How do you utilize post allogeneic transplant chimerism in clinical practice? Do you obta...
Presuming strong indication for ASA - eg history of NSTEMI
In patients who continue to have insomnia despite diphenhydramine, benzos, and trazodone, are there other evidence based treatments that are helpful?
If so, what regimen do you utilize?
If serum markers were normal, how strongly do you consider 1 cycle of BEP for embryonal predominant pathology?
Is this an artifact of what agent prior clinical trials used or something to do with mechanism of action (ie less mineralocorticoid effect of dex)?
VIP can be considered, but given complex psychosocial issues and limited community cancer treatment resources, this question is being asked.
What is the impact among patients and providers?
Has your documentation been adjusted now that patients can readily review?
NCCN guidelines state check at baseline and then as clinically indicated. Some other sources state, can check prior to each cycle of BEP?
What ...
Does the degree of resectability affect your management?
Does treatment with B-cell depletion and/or negative anti-spike antibody status despite COVID mRNA vaccination influence your decision?
Such as the case in which a patient is unresponsive to steroids, IVIG, TPO-agonist, rituximab, splenectomy, and even fostamitinib.
e.g. DITP from eptifibatide after a cardiac intervention
IVIG, TPO, or other agents?
Given persistent embryonal histology on RPLND, do you favor observation or TIP/VIP? What do you use to guide your decision?
How does your treatment approach vary depending on the underlying predisposition?
Given the POLARIX study data presented at ASH 2021, will this replace R-CHOP as the standard of care therapy in your practice? If not, how will y...
Would you offer indefinite anticoagulation if the event is unprovoked and the patient has low bleeding risk?
Also is there value in using voxelotor for the purpose of reducing hemolysis, and if so what parameters do you use to determine when to initiate voxel...
Is there a particular sequence you would adjust contributing antirejection or antimicrobial medications? Is the use of G-CSF appropriate and at what c...
Hydroxyurea is demonstrated to reduce complications and improve long-term outcomes in severe genotypes HbSS and sickle beta0 thalassemia. What clinica...
Are there other supportive care interventions that would otherwise be covered by hospice?
Provoked or unprovoked VTE: Do you use D-Dimer (or even repeat imaging to reassess residual clot) in any capacity to guide anticoagulation duration? E...
Have you used anticoagulants other than coumadin? Or is that the only appropriate agent given monitoring is based on PT/INR?
Do your recommendations differ between those who receive ABVD and escalated BEACOPP?
Do you recommend consultation with fertility specialists for all...
Especially with the current drug shortage of nelarabine.
While building a trusting patient-physician relationship, what therapies could be discussed that may be aligned with naturopathic medicine? (i.e. L-gl...
Does manipulation of blood products (leukoreduction, irradiated) affect your approach? There is growing evidence that routine premedication (at least ...
In particular, is there any data on the efficacy of Ipilimumab/Nivolumab?
While this is a known risk factor for venous [Meijers et al NEJM 2000] and potentially arterial [Yang et al, Am J Clin Pathol 2006] thrombosis, it is ...
Would this change with someone who has a history of thrombosis (e.g. DVT/PE, MI, CVA)?
Would this change with someone who is more fit vs more frail?
Results of AHOD1331 are not yet known, but adults have started using Brentuximab upfront for high risk patients
Such as patients who are frail, elderly, renally impaired?
Would you consider sirolimus over cyclosporine or tacrolimus for safer nephrotoxicity prof...
How often do you monitor ADAMTS-13 levels off therapy?
For example, do we prefer one regimen over the other in patients with a bleeding history or who have relapsed after a lengthy remission?
In follow up to @Jacqueline Casillas presentation at ASCO 2021 regarding models of survivorship care delivery for AYA patients.
If given both options, which donor would one prefer: haploidentical related donor or 7/8 mismatched unrelated donor using post transplant cyclophospha...
NCCN guideline V4.2021 DLBCL page BCEL-3 states stage I-II, bulky >= 7.5cm should be treated with 6 cycles of RCHOP, but most bone lymphoma studies...
Is there a role for empiric antibiotics if there is history of opportunistic infection?
Would you plan straight pediatric dosing using 2500 Units/m2 or a cap of 3750 Units as used in some adult ALL regimens due to excess liver/pancreas to...
s/p optimal debulking.
If this was an early-stage cancer would it change your adjuvant therapy recommendations?
Do you follow the 2019 EULAR Guidelines that SLE patients with asymptomatic, positive aPL should be on low-dose ASA?
Would you use ALK inhibitors such as crizotinib based on recent phase II data?
Are there any research efforts to combine ALK inhibitors with current ...
Do you always treat with the full 21-day treatment course, or can defibrotide be stopped if certain criteria are met sooner?
Do you prefer a cHL chemotherapy backbone or PMBL chemotherapy backbone?
While thrombophilia testing is not routinely recommended prior to starting OCPs, how about after the development of a VTE?
Would you give a trial of IST first or immediately refer for SCT if the patient has matched siblings?
During the Stimate recall, how are we performing DDAVP challenges for newly diagnosed hemophilia A or von Willebrand disease?
How do you "have the talk" in a way that is straightforward without emotionally crushing the patient?
Have the RAPID or CALGB 5064 studies changed your treatment approach?
Specifically, are there strategies you use to 1) empower patients to participate in decision-making and 2) reassure patients who may be skeptical?
Presented at ASH: FLIGHT trial
If standard of care BEP chemo, tandem transplant, and radiation to primary site have been done previously.
What is the lowest level you have seen with uncomplicated or complicated crises?
There are various formulations of intravenous iron; each with varying costs, test dose requirement, elemental dose, and number or time of infusions ne...
There are mixed recommendations about re-testing vs simply waiting for a quarantine period prior to resuming therapy.
Is there a preferred strategy of transfusional support versus reduced-dose anticoagulation during the duration of thrombocytopenia?
What if this was "triple-negative" antiphospholipid syndrome?
I have heard <20% MRD. What about proceeding if patient is hypoplastic after chemotherapy?
After optimizing symptoms and reversible factors, and attempting cognitive-behavioral interventions and exercise, do you recommend pharmacologic agent...
Presented with mass projecting into right/left anterior ethmoid complex
CT scans show omental and pelvic disease.
Would you consider “bridging” therapy with something like an HMA?
Is it at neutrophil recovery, at documentation of CR on bone marrow biopsy, or is there a different point in time?
Does acute leukemia sub-type affect your decision?
What are there most evidence-based options?
E.g. a patient with progression of their primary cancer but still is testing COVID19+ over a month after infection?
Are you placing more weight on patient risk factors such as age >65 or co-morbidities?
What if the patient has a history of confirmed COVID-19 but has since recovered?
Discussion of treatment options for midline low-grade glioma causing life-altering symptoms in a pregnant patient to avoid teratogenicity.
At what age would you treat an early stage hodgkins lymphoma patient with ABVD + RT (adult treatment) vs OEPA x 2 or AV-PC x 3 (pediatric paradigm)?&n...
Do you limit it to post-pubertal patients? Do you offer it only if they will proceed with bone marrow transplantation after CAR-T?
GI work up negative. NGS cancer type and isochromosome 12p ordered and pending. Pathology at RPLND was negative for cancer.
Obviously, patient and caregiver preferences are paramount. But, what factors do you consider? Does expanded hospice (e.g., Medicare Care Choices) inf...
Acknowledging that there is no time for good trials yet in this setting
How would you approach a patient who is receiving chemoRT but has confirmed COVID-19 with minor symptoms, as breaking treatment for 2 weeks quarantine...
-The data on induction for adult H&N ca has been mixed (excluded NPX) but recent data suggest a benefit for adult NPX.
-Given that this is standa...
Is there a role for immunotherapy outside of trial setting?
What dose do you recommend?
My patient’s family has asked that I don’t tell her that she has metastatic cancer because it will devastate her. I am planning on palliat...
1077515224150311211149941487314957148681475911905146779376146521468413753142461440814251111711417013865138351384513687136401244813183135201347912999134211140812949128531095712817128026074122241256812532121131231212331121611233412253880711567861011975117981190311797117581143811643115971157097591127611296111271112881258364108731080992861085510625106539681105111032510552103171042090491040894829834103021017986061011410013100231003999639923976898849844974140319536956396129492926393779219922592078521919191688235238892390118810868888178832877986408580849481148034797578507436769075727661752659444003739572797104676993271147108694170347035644369306768677868106718672961653764862297
Papers discussed in this category
JAMA,
Gynecol Oncol, 2019 Aug 16
Cancer, 2004-08-15
Br. J. Haematol., 2003-11-01
Br. J. Haematol., 1998-08-01
Cancer, 1990-11-15
Radiother Oncol, 1990-01-01
Clin. Cancer Res.,
Fertil. Steril., 2013 Sep 05
J. Clin. Oncol., 2019 Sep 25
Lancet Oncol., 2020 Feb 14
Ann. Oncol., 2020 Mar 26
J. Clin. Oncol., 2019 Sep 10
Journal of the National Cancer Institute, 2005-09-21
Eur. J. Cancer,
Br. J. Cancer, 2007 Jan 30
American journal of hematology, 2018-08
Blood, 2019-04-04
Am. J. Hematol., 2019 Nov 19
J. Neurosurg., 2017 Mar 03
Acta Neurochir (Wien), 2019 Jan 29
J. Neurooncol., 2018 Apr 06
Proceedings of the National Academy of Sciences of the United States of America, 2015-11-03
Oncologist, 2020 Mar 10
Semin Diagn Pathol, 2016 Dec 23
The New England journal of medicine, 2007-01-25
Haematologica, 2020
Nature, 2019-03
Blood, 2018 May 02
Leuk Lymphoma, 2019 Dec 26
Journal of the National Cancer Institute, 2013-08-21
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2010-02
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-09-01
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2016-04
Blood, 2018 Jul 12
Ann. Intern. Med., 2019 Oct 15
Blood Transfus, 2018 Oct 24
J Thromb Haemost, 2018 May 08
The New England journal of medicine, 2017-02-02
Blood, 2009 Nov 10
Clin Lymphoma Myeloma Leuk, 2017 Mar 07
American journal of hematology, 2011-10
The American journal of medicine, 2017-12
American journal of hematology, 2018-05
Am J Hematol, 2020 Jun 29
Am J Hematol, 2019 Sep
Am J Hematol, 2018 Jun
JAMA,
N Engl J Med,
The journal of allergy and clinical immunology. In practice, 2017
Archives of surgery (Chicago, Ill. : 1960), 2008-07
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2018-01
Ann Surg,
N. Engl. J. Med., 2015-04-23
Blood, 2018 Sep 6
J Clin Oncol, 2017 Mar 14
Blood, 2020 Sep 23
The Lancet. Oncology, 2017-11
The Lancet. Oncology, 2018-03
The Lancet. Oncology, 2019-06
J Hematol Oncol, 2016 Jun 03
Blood, 2013-12-05
Blood Adv,
Blood,
Blood, 2013 Sep 19
The Lancet. Haematology, 2015-09
Haematologica, 2017-07
American journal of hematology, 2019-04
Cancer medicine, 2019-01
Journal of the National Cancer Institute, 1988-07-06
Annals of oncology : official journal of the European Society for Medical Oncology, 2015-02
Anticancer Drugs,
J Adolesc Young Adult Oncol, 2019 Nov 08
N. Engl. J. Med., 2018-01-25
Bone Marrow Transplant, 2019 Oct 01
Front Immunol, 2020 Apr 03
Blood, 2021 Mar 08
Gynecologic oncology, 2016-01
Gynecol Oncol, 2020 Jul 9
Gynecol Oncol, 2020 Jul 25
J Clin Oncol, 2021 Apr 07
Ann Oncol, 2007 Nov 15
Leuk Lymphoma, 2019 Nov 04
Seminars in hematology, 2013-07
Pediatr Blood Cancer, 2019 Jul 24
J. Clin. Oncol., 2020 Feb 14
Cancer, 2020 May 19
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-02-01
Cancer, 2020 Mar 15
J Clin Oncol, 2021 Apr 06
Ann Oncol, 2021 Mar 18
Clin Transl Oncol, 2020 Sep 17
J Assist Reprod Genet, 2020 Jun 02
Lancet Oncol, 2018 Sep 13
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-02-20
Lancet (London, England), 2010-12-11
Blood, 2012 Apr 04
Clin Lymphoma Myeloma Leuk, 2019 Sep 30
Bone Marrow Transplant, 2018 Jun 08
J Clin Oncol, 2020 Apr 10
The Lancet. Oncology, 2017-09
Blood, 2016-07-14
Blood, 2016 Sep 26
Transfusion, 2020 Sep 24
Lancet Haematol,
British journal of haematology, 2014-06
International journal of radiation oncology, biology, physics, 2019-06-01
Annals of oncology : official journal of the European Society for Medical Oncology, 2007-04
Blood, 2018-07-05
Blood,
Blood,
J Clin Oncol, 2021 Jun 25
Blood, 2019-06-06
Eur J Haematol, 2021 Feb 17
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2011-10
Journal of oncology practice, 2019-01
Support Care Cancer, 2021 Aug 16
Arthritis Rheumatol, 2021 Apr 01
The New England journal of medicine, 1981-09-24
Ann Intern Med,
Cancer, 2011 Feb 01
Practical radiation oncology, 2019-03
Cancer Cell, 2020 Oct 08
J Gen Intern Med, 2021 Feb 02
JAMA Netw Open, 2020 Jun 01
Blood, 2008-02-15
Blood, 2016-07-28
Blood advances, 2016-12-27
The Lancet. Haematology, 2018-12
N Engl J Med,
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015-04
Pediatr Blood Cancer, 2019 Jul 31
Journal of hospital medicine, 2018-08-01
Front Oncol, 2022 Mar 09
BMJ Support Palliat Care, 2022 Jul 08
Nutr Cancer, 2019 Oct 12
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-03-01
Sci Rep, 2020 Jul 01
Neuro Oncol,
Annals of oncology : official journal of the European Society for Medical Oncology, 1993-11
Gastroenterology, 1993-06
Gastroenterology, 1991 Jul
Z Naturforsch C J Biosci, 2002 Mar-Apr
Immunopharmacol Immunotoxicol, 2003 Nov
Exp Toxicol Pathol, 2002 Feb
Biochem Biophys Res Commun, 1999 Sep 24
Ital J Gastroenterol Hepatol, 1998 Dec
Chem Biol Interact, 2001 Dec 21
Metal-based drugs, 2010
J Allergy Clin Immunol Pract, 2019 Feb 15
Pediatr Blood Cancer, 2021 Apr 12
The Lancet. Haematology, 2019-03
J Clin Oncol, 2021 Dec 02
Urology, 1982-09
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2009-03
Clin Infect Dis, 2005 Jan 21
Pediatr Transplant, 2014 Sep 08
J Clin Oncol, 2021 Apr 30
Pediatr Infect Dis J, 2014 Nov
Bone Marrow Transplant, 2006 Mar
Clinical cancer research : an official journal of the American Association for Cancer Research, 2008-01-15
Eur J Clin Pharmacol, 2001 Aug
JAMA Netw Open, 2021 Aug 02
Blood, 2006-05-01
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-02-01
Blood, 2017-03-09
The Lancet. Oncology, 2015-10
N Engl J Med, 2013 Jul 11
Blood, 2012 Jun 19
Genetic epidemiology, 2016-09
American journal of hematology, 2019-03
Blood, 2021 Jan 07
Blood, 2019-04-11
N Engl J Med, 2022 Dec 11
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-02-01
Obstet Gynecol, 1998 Oct
Acta Oncol, 2019 Apr 08
Journal of neurosurgery, 2013-04
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-05-01
Cochrane Database Syst Rev, 2020 Apr 28
J Clin Pharmacol, 2021 Jul 16